Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder.
about
Neuroplasticity and the next wave of antidepressant strategiesDifferential and converging molecular mechanisms of antidepressants' action in the hippocampal dentate gyrusCentral serotonin-2A (5-HT2A) receptor dysfunction in depression and epilepsy: the missing link?Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature.Effects of clozapine, haloperidol, and fluoxetine on the reversal of cocaine-induced locomotor sensitization.Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.5-HT2 ligands in the treatment of anxiety and depression.Aripiprazole in the treatment of Alzheimer's disease.Rational site-directed pharmacotherapy for major depressive disorder.Quinoline- and isoquinoline-sulfonamide analogs of aripiprazole: novel antipsychotic agents?Practitioner Review: The effects of atypical antipsychotics and mood stabilisers in the treatment of depressive symptoms in paediatric bipolar disorder.The modulation of adult neuroplasticity is involved in the mood-improving actions of atypical antipsychotics in an animal model of depression.Aripiprazole in the treatment of refractory mood disorders: a case series.5-HT₂A receptor inactivation potentiates the acute antidepressant-like activity of escitalopram: involvement of the noradrenergic system.Neuroprotection by aripiprazole against β-amyloid-induced toxicity by P-CK2α activation via inhibition of GSK-3β.The combination of escitalopram and aripiprazole: Investigation of psychomotor effects in rats.A framework to avoid irrational polypharmacy in psychiatry.
P2860
Q21129480-9621FEB6-484E-4FC0-B6B8-75347113E78CQ27311267-33781343-1497-4974-932C-7778F16CE5CAQ28080944-8EBE31C7-0368-4623-BB39-673D6BB60EF1Q34330761-BEBF5DC2-A31F-492E-A9D1-E556D0B31695Q34476507-0245DAD3-710A-4D8D-B99F-A88D528CAF12Q34629315-CDA7EFB3-D632-4EDB-A013-B5D68A201731Q38037141-7300709E-3040-4609-9AFD-979D863DBF96Q38076765-51CF7689-2BFC-4EE8-B5CB-946CD73F0712Q38112732-C232D6E9-D1A1-4B5D-B5F7-3E09DD28AE8CQ38172958-0D193E21-E214-4DA1-90EE-C25272B047C8Q39285492-D1E14F7E-88D2-4738-9339-1C2B8B3BB1EBQ41194085-333A0EF5-63ED-4C73-A914-5A5738D6A243Q42860058-7A25AD5C-4D11-41AC-96A9-291D10EB47F8Q45902720-A43C27E1-2CD2-4306-BF21-9386DB9442C8Q47170401-1DE86A6D-3240-407B-BC74-705346393BD4Q48001079-486575A5-D2AB-46CA-835C-83AFADA42849Q50750295-EA13F70B-8B50-4C26-896D-FAB5B9F9EAD7
P2860
Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Neurobiological bases and clin ...... ant major depressive disorder.
@en
Neurobiological bases and clin ...... ant major depressive disorder.
@nl
type
label
Neurobiological bases and clin ...... ant major depressive disorder.
@en
Neurobiological bases and clin ...... ant major depressive disorder.
@nl
prefLabel
Neurobiological bases and clin ...... ant major depressive disorder.
@en
Neurobiological bases and clin ...... ant major depressive disorder.
@nl
P1476
Neurobiological bases and clin ...... ant major depressive disorder.
@en
P2093
Claude Blondeau
Pierre Blier
P356
10.1016/S0165-0327(11)70003-9
P478
128 Suppl 1
P577
2011-01-01T00:00:00Z